Synovial sarcoma X breakpoint 1 protein (SSX1)

Synovial sarcoma X breakpoint 1 protein (SSX1) is a member of a highly homologous family of cancer/testis antigens, predominantly expressed in various cancers but with restricted expression in normal tissues to germ cells and fetal mesenchymal stem cells[1][3][5]. SSX1 functions as a transcriptional corepressor, likely modulating gene expression through interaction with chromatin-regulating complexes (polycomb group proteins, histones) and other partners such as β-catenin[1][2]. This regulation impacts proliferation, cell cycle progression, survival, and invasive/EMT phenotypes in tumor cells[1][2]. SSX1 is implicated as an oncogenic driver, especially via fusion gene events (SS18–SSX) in synovial sarcoma, and has high antigenicity, making it an attractive candidate for immunotherapeutic targeting in cancer[3][5]. Its therapeutic relevance is supported by spontaneous cellular and humoral immune responses observed in cancer patients, and ongoing research aims to harness these responses through vaccine approaches. SSX1 is also used as a biomarker for various advanced cancers due to its correlation with poor prognosis and disease progression[3][5].

Other names

SSX family member 1SSX1Cancer/testis antigen 5.1CT5.1Synovial sarcoma, X breakpoint 1SPGFX5SSRCProtein SSX1Sarcoma, synovial, X-chromosome-related 1

Rendering tumor cells immunogenic to stimulate anti-tumor immune response (tumor vaccination) Possible disruption of SSX-mediated transcriptional regulation and suppression of proliferation